Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2023 filed with the SEC

September 1, 2023March 10, 2025 Alterity Therapeutics

XBRL 30 June 2023 filed with the SEC

2023

Post navigation

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Related Posts

Prana receives A$3.3 million R&D Tax Incentive

March 18, 2019August 16, 2022

Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track

July 17, 2013August 16, 2022

Appendix 4C – Q3 FY22 Quarterly Cash Flow Report

April 29, 2022August 16, 2022

Recent Posts

Target Market Determination – Placement Offer
Target Market Determination – Broker Offer
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065